
Lord Abbett
Quarterly Portfolio Holdings Report
Lord Abbett
Developing Growth Fund
For the period ended October 31, 2021
Schedule of Investments (unaudited)
October 31, 2021
Investments | | Shares | | | Fair Value (000) | |
LONG-TERM INVESTMENTS 99.79% | | | | | | | | |
COMMON STOCKS 99.79% | | | | | | | | |
| | | | | | | | |
Aerospace & Defense 2.69% | | | | | | | | |
Axon Enterprise, Inc.* | | | 562,308 | | | $ | 101,193 | |
CAE, Inc. (Canada)*(a) | | | 1,144,880 | | | | 34,770 | |
Total | | | | | | | 135,963 | |
| | | | | | | | |
Auto Components 1.86% | | | | | | | | |
Fox Factory Holding Corp.* | | | 388,138 | | | | 62,471 | |
Gentherm, Inc.* | | | 428,735 | | | | 31,568 | |
Total | | | | | | | 94,039 | |
| | | | | | | | |
Banks 2.59% | | | | | | | | |
Silvergate Capital Corp. Class A* | | | 451,113 | | | | 70,653 | |
Western Alliance Bancorp | | | 517,624 | | | | 60,091 | |
Total | | | | | | | 130,744 | |
| | | | | | | | |
Beverages 1.73% | | | | | | | | |
Celsius Holdings, Inc.* | | | 687,410 | | | | 66,349 | |
Duckhorn Portfolio, Inc. (The)* | | | 1,088,547 | | | | 21,052 | |
Total | | | | | | | 87,401 | |
| | | | | | | | |
Biotechnology 13.85% | | | | | | | | |
ALX Oncology Holdings, Inc.* | | | 494,209 | | | | 27,696 | |
Arena Pharmaceuticals, Inc.* | | | 395,393 | | | | 22,692 | |
Biohaven Pharmaceutical Holding Co. Ltd.* | | | 340,543 | | | | 48,466 | |
Blueprint Medicines Corp.* | | | 484,435 | | | | 54,494 | |
Bridgebio Pharma, Inc.* | | | 706,258 | | | | 34,875 | |
CareDx, Inc.* | | | 537,452 | | | | 27,410 | |
Cerevel Therapeutics Holdings, Inc.*(b) | | | 628,604 | | | | 25,553 | |
Curis, Inc.* | | | 2,127,856 | | | | 13,831 | |
Intellia Therapeutics, Inc.* | | | 444,407 | | | | 59,097 | |
Karuna Therapeutics, Inc.* | | | 193,760 | | | | 27,200 | |
Krystal Biotech, Inc.* | | | 689,547 | | | | 34,540 | |
Mirati Therapeutics, Inc.* | | | 384,068 | | | | 72,597 | |
Natera, Inc.* | | | 743,870 | | | | 85,225 | |
Investments | | Shares | | | Fair Value (000) | |
Biotechnology (continued) | | | | | | | | |
Rocket Pharmaceuticals, Inc.* | | | 683,951 | | | $ | 20,320 | |
Sarepta Therapeutics, Inc.* | | | 251,764 | | | | 19,922 | |
SpringWorks Therapeutics, Inc.* | | | 274,902 | | | | 18,435 | |
TG Therapeutics, Inc.* | | | 990,531 | | | | 30,924 | |
Turning Point Therapeutics, Inc.* | | | 333,269 | | | | 13,857 | |
Ultragenyx Pharmaceutical, Inc.* | | | 385,419 | | | | 32,344 | |
Xenon Pharmaceuticals, Inc. (Canada)*(a) | | | 982,271 | | | | 30,598 | |
Total | | | | | | | 700,076 | |
| | | | | | | | |
Building Products 1.76% | | | | | | | | |
AZEK Co., Inc. (The)* | | | 1,373,869 | | | | 50,407 | |
Trex Co., Inc.* | | | 363,064 | | | | 38,630 | |
Total | | | | | | | 89,037 | |
| | | | | | | | |
Capital Markets 1.86% | | | | | | | | |
Evercore, Inc. Class A | | | 498,286 | | | | 75,660 | |
Open Lending Corp. Class A* | | | 589,846 | | | | 18,592 | |
Total | | | | | | | 94,252 | |
| | | | | | | | |
Chemicals 2.16% | | | | | | | | |
Balchem Corp. | | | 341,272 | | | | 52,245 | |
Livent Corp.* | | | 2,012,585 | | | | 56,795 | |
Total | | | | | | | 109,040 | |
| | | | | | | | |
Communications Equipment 2.18% | | | | | | | | |
Calix, Inc.* | | | 1,762,674 | | | | 110,326 | |
| | | | | | | | |
Construction & Engineering 0.37% | | | | | | | | |
Ameresco, Inc. Class A* | | | 226,580 | | | | 18,609 | |
| | | | | | | | |
Construction Materials 0.95% | | | | | | | | |
Eagle Materials, Inc. | | | 322,771 | | | | 47,886 | |
| | | | | | | | |
Diversified Consumer Services 0.23% | | | | | | | | |
Duolingo, Inc.*(b) | | | 66,158 | | | | 11,491 | |
| | | | | | | | |
Electronic Equipment, Instruments & Components 1.16% | |
Littelfuse, Inc. | | | 200,065 | | | | 58,929 | |
| See Notes to Schedule of Investments. | 1 |
Schedule of Investments (unaudited)(continued)
October 31, 2021
Investments | | Shares | | | Fair Value (000) | |
Energy Equipment & Services 0.22% | | | | | | |
MELI Kaszek Pioneer Corp. Class A* | | | 895,435 | | | $ | 11,238 | |
| | | | | | | | |
Health Care Equipment & Supplies 7.82% | | | | | | | | |
Axonics, Inc.* | | | 1,211,215 | | | | 88,843 | |
Figs, Inc. Class A*(b) | | | 1,059,041 | | | | 35,594 | |
Inmode Ltd. (Israel)*(a) | | | 1,194,417 | | | | 113,159 | |
Ortho Clinical Diagnostics Holdings plc* | | | 1,148,499 | | | | 22,706 | |
Shockwave Medical, Inc.* | | | 446,320 | | | | 95,379 | |
Tandem Diabetes Care, Inc.* | | | 292,901 | | | | 39,931 | |
Total | | | | | | | 395,612 | |
| | | | | | | | |
Health Care Technology 2.57% | | | | | | | | |
Inspire Medical Systems, Inc.* | | | 323,843 | | | | 87,302 | |
Phreesia, Inc.* | | | 605,364 | | | | 42,702 | |
Total | | | | | | | 130,004 | |
| | | | | | | | |
Hotels, Restaurants & Leisure 1.94% | | | | | | | | |
Marriott Vacations Worldwide Corp. | | | 327,368 | | | | 51,469 | |
Papa John’s International, Inc. | | | 375,678 | | | | 46,614 | |
Total | | | | | | | 98,083 | |
| | | | | | | | |
Household Durables 4.03% | | | | | | | | |
LGI Homes, Inc.* | | | 340,551 | | | | 50,844 | |
Sonos, Inc.* | | | 1,565,018 | | | | 51,051 | |
Tempur Sealy International, Inc. | | | 1,841,456 | | | | 81,889 | |
Traeger, Inc.*(b) | | | 1,049,317 | | | | 19,822 | |
Total | | | | | | | 203,606 | |
| | | | | | | | |
Information Technology Services 6.82% | | | | | | | | |
BigCommerce Holdings, Inc.* | | | 250,404 | | | | 11,571 | |
DigitalOcean Holdings, Inc.* | | | 494,108 | | | | 48,220 | |
Endava plc ADR* | | | 645,537 | | | | 102,292 | |
Flywire Corp.*(b) | | | 531,121 | | | | 25,196 | |
Globant SA (Uruguay)*(a) | | | 226,563 | | | | 72,317 | |
Shift4 Payments, Inc. Class A* | | | 695,159 | | | | 43,886 | |
TaskUS, Inc. Class A*(b) | | | 714,945 | | | | 41,395 | |
Total | | | | | | | 344,877 | |
Investments | | Shares | | | Fair Value (000) | |
Insurance 0.83% | | | | | | |
Goosehead Insurance, Inc. Class A | | | 290,942 | | | $ | 41,983 | |
| | | | | | | | |
Interactive Media & Services 3.19% | | | | | | | | |
Bumble, Inc. Class A*(b) | | | 1,588,231 | | | | 83,414 | |
Eventbrite, Inc. Class A* | | | 1,644,853 | | | | 33,292 | |
ZipRecruiter, Inc. Class A* | | | 1,598,712 | | | | 44,412 | |
Total | | | | | | | 161,118 | |
| | | | | | | | |
Leisure Products 2.16% | | | | | | | | |
Callaway Golf Co.* | | | 1,308,384 | | | | 35,392 | |
YETI Holdings, Inc.* | | | 752,181 | | | | 73,962 | |
Total | | | | | | | 109,354 | |
| | | | | | | | |
Life Sciences Tools & Services 0.38% | | | | | | | | |
Quanterix Corp.* | | | 385,279 | | | | 19,499 | |
| | | | | | | | |
Machinery 4.88% | | | | | | | | |
Altra Industrial Motion Corp. | | | 609,878 | | | | 31,805 | |
Chart Industries, Inc.* | | | 441,518 | | | | 78,378 | |
Evoqua Water Technologies Corp.* | | | 1,251,163 | | | | 52,336 | |
Kornit Digital Ltd. (Israel)*(a) | | | 257,378 | | | | 43,054 | |
RBC Bearings, Inc.* | | | 175,914 | | | | 41,152 | |
Total | | | | | | | 246,725 | |
| | | | | | | | |
Media 0.37% | | | | | | | | |
Integral Ad Science Holding Corp.* | | | 755,182 | | | | 18,555 | |
| | | | | | | | |
Personal Products 1.05% | | | | | | | | |
Beauty Health Co. (The)*(b) | | | 1,938,051 | | | | 53,238 | |
| | | | | | | | |
Pharmaceuticals 1.22% | | | | | | | | |
Intra-Cellular Therapies, Inc.* | | | 1,430,414 | | | | 61,608 | |
| | | | | | | | |
Professional Services 1.96% | | | | | | | | |
Insperity, Inc. | | | 390,247 | | | | 48,781 | |
Upwork, Inc.* | | | 1,067,455 | | | | 50,298 | |
Total | | | | | | | 99,079 | |
2 | See Notes to Schedule of Investments. |
Schedule of Investments (unaudited)(continued)
October 31, 2021
Investments | | | Shares | | | | Fair Value (000) | |
Semiconductors & Semiconductor Equipment 9.66% | |
Ambarella, Inc.* | | | 408,496 | | | $ | 75,911 | |
Brooks Automation, Inc. | | | 606,541 | | | | 70,632 | |
CEVA, Inc.* | | | 516,218 | | | | 23,545 | |
Diodes, Inc.* | | | 941,201 | | | | 90,440 | |
MKS Instruments, Inc. | | | 255,242 | | | | 38,299 | |
Semtech Corp.* | | | 1,129,948 | | | | 96,079 | |
Silicon Motion Technology Corp. ADR | | | 603,742 | | | | 43,113 | |
SiTime Corp.* | | | 190,354 | | | | 50,423 | |
Total | | | | | | | 488,442 | |
| | | | | | | | |
Software 9.62% | | | | | | | | |
Appian Corp.*(b) | | | 222,332 | | | | 22,102 | |
Asana, Inc. Class A* | | | 325,861 | | | | 44,252 | |
Clear Secure, Inc. Class A*(b) | | | 476,750 | | | | 21,306 | |
Everbridge, Inc.* | | | 393,191 | | | | 62,639 | |
Jamf Holding Corp.* | | | 1,409,925 | | | | 67,183 | |
Lightspeed Commerce, Inc. (Canada)*(a) | | | 380,605 | | | | 37,181 | |
Olo Inc. Class A* | | | 686,250 | | | | 18,680 | |
Rapid7, Inc.* | | | 693,662 | | | | 89,309 | |
Riskified Ltd. Class A (Israel)*(a) | | | 926,069 | | | | 17,910 | |
Sprinklr, Inc. Class A*(b) | | | 854,938 | | | | 16,501 | |
Sprout Social, Inc. Class A* | | | 698,850 | | | | 89,229 | |
Total | | | | | | | 486,292 | |
| | | | | | | | |
Specialty Retail 3.72% | | | | | | | | |
Boot Barn Holdings, Inc.* | | | 287,944 | | | | 30,087 | |
National Vision Holdings, Inc.* | | | 1,206,051 | | | | 74,341 | |
Petco Health & Wellness Co., Inc.*(b) | | | 1,350,593 | | | | 33,400 | |
RH* | | | 76,612 | | | | 50,536 | |
Total | | | | | | | 188,364 | |
| | | | | | | | |
Textiles, Apparel & Luxury Goods 2.69% | | | | | | | | |
Crocs, Inc.* | | | 841,791 | | | | 135,907 | |
Investments | | Shares | | | Fair Value (000) | |
Trading Companies & Distributors 1.27% | | | | | | |
Rush Enterprises, Inc. Class A | | | 1,233,744 | | | $ | 64,253 | |
Total Common Stocks (cost $3,630,538,626) | | | | | | | 5,045,630 | |
| | | | | | | | |
| | Principal Amount (000) | | | | |
| | | | | | | | |
SHORT-TERM INVESTMENTS 3.05% | | | | | | | | |
| | | | | | | | |
Repurchase Agreements 0.38% | | | | | | | | |
| | | | | | | | |
Repurchase Agreement dated 10/29/2021, 0.00% due 11/1/2021 with Fixed Income Clearing Corp. collateralized by $20,675,600 of U.S. Treasury Note at .50% due 10/31/2027; value: $19,729,295; proceeds: $19,342,444 (cost $19,342,444) | | $ | 19,342 | | | | 19,342 | |
| | | | | | | | |
| | Shares | | | | |
| | | | | | | | |
Money Market Funds 2.40% | | | | | | | | |
Fidelity Government Portfolio(c) (cost $121,361,390) | | | 121,361,390 | | | | 121,361 | |
| | | | | | | | |
Time Deposits 0.27% | | | | | | | | |
CitiBank N.A.(c) (cost $13,484,599) | | | 13,484,599 | | | | 13,485 | |
Total Short-Term Investments (cost $154,188,433) | | | | | | | 154,188 | |
Total Investments in Securities 102.84% (cost $3,784,727,059) | | | | | | | 5,199,818 | |
Other Assets and Liabilities – Net (2.84)% | | | | | | | (143,556 | ) |
Net Assets 100.00% | | | | | | $ | 5,056,262 | |
ADR | | American Depositary Receipt. |
* | | Non-income producing security. |
(a) | | Foreign security traded in U.S. dollars. |
(b) | | All or a portion of this security is temporarily on loan to unaffiliated broker/dealers. |
(c) | | Security was purchased with the cash collateral from loaned securities. |
| See Notes to Schedule of Investments. | 3 |
Schedule of Investments (unaudited)(concluded)
October 31, 2021
The following is a summary of the inputs used as of October 31, 2021 in valuing the Fund’s investments carried at fair value(1):
Investment Type(2) | | Level 1 (000) | | | Level 2 (000) | | | Level 3 (000) | | | Total (000) | |
Long-Term Investments | | | | | | | | | | | | | | | | |
Common Stocks | | $ | 5,045,630 | | | $ | – | | | $ | – | | | $ | 5,045,630 | |
Short-Term Investments | | | | | | | | | | | | | | | | |
Repurchase Agreements | | | – | | | | 19,342 | | | | – | | | | 19,342 | |
Money Market Funds | | | 121,361 | | | | – | | | | – | | | | 121,361 | |
Time Deposits | | | – | | | | 13,485 | | | | – | | | | 13,485 | |
Total | | $ | 5,166,991 | | | $ | 32,827 | | | $ | – | | | $ | 5,199,818 | |
(1) | | Refer to Note 2(b) for a description of fair value measurements and the three-tier hierarchy of inputs. |
(2) | | See Schedule of Investments for fair values in each industry and identification of foreign issuers and/or geography. When applicable each Level 3 security is identified on the Schedule of Investments along with the valuation technique utilized. |
| | |
| | A reconciliation of Level 3 investments is presented when the Fund has a material amount of Level 3 investments at the beginning or end of the period in relation to the Fund’s net assets. |
4 | See Notes to Schedule of Investments. |
Notes to Schedule of Investments (unaudited)
1. ORGANIZATION
Lord Abbett Developing Growth Fund, Inc. (the “Fund”) is registered under the Investment Company Act of 1940, as amended (the “Act”), as a diversified, open-end management investment company. The Fund was incorporated under Maryland law on August 21, 1978. The Fund’s predecessor corporation was organized on July 11, 1973.
The Fund’s investment objective is long-term growth of capital through a diversified and actively managed portfolio consisting of developing growth companies, many of which are traded over the counter.
2. SIGNIFICANT ACCOUNTING POLICIES
(a) | Investment Valuation-Under procedures approved by the Fund’s Board of Directors (the “Board”), Lord, Abbett & Co. LLC (“Lord Abbett”), the Fund’s investment manager, has formed a Pricing Committee to administer the pricing and valuation of portfolio investments and to ensure that prices utilized reasonably reflect fair value. Among other things, these procedures allow the Fund to utilize independent pricing services, quotations from securities and financial instrument dealers and other market sources to determine fair value. |
| |
| Securities actively traded on any recognized U.S. or non-U.S. exchange or on The NASDAQ Stock Market LLC are valued at the last sale price or official closing price on the exchange or system on which they are principally traded. Events occurring after the close of trading on non-U.S. exchanges may result in adjustments to the valuation of foreign securities to reflect their fair value as of the close of regular trading on the New York Stock Exchange LLC. The Fund may rely on an independent fair valuation service in adjusting the valuations of foreign securities. Unlisted equity securities are valued at the last quoted sale price or, if no sale price is available, at the mean between the most recently quoted bid and asked prices. |
| |
| Securities for which prices are not readily available are valued at fair value as determined by the Pricing Committee and approved in by the Board. The Pricing Committee considers a number of factors, including observable and unobservable inputs, when arriving at fair value. The Pricing Committee may use related or comparable assets or liabilities, recent transactions, market multiples, book values and other relevant information to determine fair value of portfolio investments. The Board convenes on a regular basis to review fair value determinations made by the Pricing Committee pursuant to the procedures and employs techniques such as reviews of any related market activity, transactional back-testing disposition analysis and regular review of inputs and assumptions. |
| |
| Investments in open-end money market mutual funds are valued at their NAV as of the close of each business day. Short-term securities with 60 days or less remaining to maturity are valued using the amortized cost method, which approximates fair value. |
| |
(b) | Fair Value Measurements-Fair value is defined as the price that the Fund would receive upon selling an investment or transferring a liability in an orderly transaction to an independent buyer in the principal or most advantageous market of the investment. A three-tier hierarchy is used to maximize the use of observable market data and minimize the use of unobservable inputs and to establish classification of fair value measurements for disclosure purposes. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk - for example, the risk inherent in a particular valuation technique used to measure fair value (such as a pricing model) and/or the |
5
Notes to Schedule of Investments (unaudited)(continued)
| risk inherent in the inputs to the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability. Observable inputs are based on market data obtained from sources independent of the reporting entity. Unobservable inputs reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset or liability. Unobservable inputs are based on the best information available in the circumstances. The three-tier hierarchy classification is determined based on the lowest level of inputs that is significant to the fair value measurement, and is summarized in the three broad Levels listed below: |
| • | Level 1 – | unadjusted quoted prices in active markets for identical investments; |
| | | |
| • | Level 2 – | other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.); and |
| | | |
| • | Level 3 – | significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments). |
| A summary of inputs used in valuing the Fund’s investments as of October 31, 2021 and, if applicable, Level 3 rollforwards for the period then ended is included in the Fund’s Schedule of Investments. |
| |
| Changes in valuation techniques may result in transfers into or out of an assigned level within the three-tier hierarchy. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. |
3. FEDERAL TAX INFORMATION
It is the policy of the Fund to meet the requirements of Subchapter M of the Internal Revenue Code applicable to regulated investment companies and to distribute substantially all taxable income and capital gains to its shareholders. Therefore, no income tax provision is required.
Each Fund files U.S. federal and various state and local tax returns. No income tax returns are currently under examination. The statute of limitations on the Fund’s filed U.S. federal tax returns remains open generally three years after the filing of the tax return. The statutes of limitations on the Fund’s, state and local tax returns may remain open for an additional year depending upon the jurisdiction.
4. SECURITIES LENDING AGREEMENT
The Fund has established a securities lending agreement with Citibank, N.A. (the “agent”) for the lending of securities to qualified brokers in exchange for securities or cash collateral equal to at least the market value of securities loaned, plus interest, if applicable. Cash collateral is invested in an approved money market fund. In accordance with the Fund’s securities lending agreement, the market value of securities on loan is determined each day at the close of business and any additional collateral required to cover the value of securities on loan is delivered to the Fund on the next business day. As with other extensions of credit, the Fund may experience a delay in the recovery of its securities or incur a loss should the borrower of the securities breach its agreement with the Fund or has become insolvent at a time when the collateral is insufficient to cover the cost of repurchasing securities on loan.
6
Notes to Schedule of Investments (unaudited)(concluded)
As of October 31, 2021, the market value of securities loaned and collateral received for the Fund was as follows:
Market Value of Securities Loaned | Collateral Received | |
132,878,825 | 134,845,989 | |
7
QPHR-DEV-1Q
(10/21)